

University of Groningen

The human dimension in the assessment of medicines

Beyer, Andrea Rose-Marie

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:
2015

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Beyer, A. R.-M. (2015). *The human dimension in the assessment of medicines: Perception, preferences, and decision making in the European regulatory environment*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

The Human Dimension in the Assessment of Medicines

Perception, Preferences, and Decision Making in the European
Regulatory Environment

Andrea Rose-Marie Beyer

The studies presented in this thesis were performed in the context of the Escher Project (T6-202), a project of the Dutch Top Institute Pharma. The Escher project focuses on delivering evidence and credibility for regulatory reform and policy recommendations.

This thesis was performed in collaboration with the European Medicines Agency, London, United Kingdom.

§ Disclaimer

The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agencies or one of its committees or working parties.

Cover, layout and printing: Off Page, Amsterdam

ISBN: 978-94-6182-614-5

Copyright © 2015 by Andrea R. Beyer



**university of
 groningen**

The Human Dimension in the Assessment of Medicines

Perception, Preferences, and Decision Making in the European
Regulatory Environment

PhD thesis

to obtain the degree of PhD at the
University of Groningen
on the authority of the
Rector Magnificus Prof. E. Sterken
and in accordance with
the decision by the College of Deans.
This thesis will be defended in public on
Wednesday 28 October 2015 at 11.00 hours

by

Andrea Rose-Marie Beyer

born on 4 January 1967
in St Thomas, Jamaica

Supervisors

Prof. J.L. Hillege

Prof. P.A. de Graeff

Co-supervisor

Prof. B. Fasolo

Assessment Committee

Prof. H.G.M. Leufkens

Prof. P. Denig

Prof. M.J. IJzerman

'In general, there is a degree of doubt, caution, and modesty, which, in all kinds of scrutiny and decision ought to forever accompany a just reasoner.'

David Hume, 1789

Philosopher of the Scottish Enlightenment

TABLE OF CONTENTS

Chapter 1	Introduction	9
Chapter 2	Measuring Risk Perception	27
Chapter 2.1	Risk perception of prescription drugs	29
	Annex 1_Questionnaire 1	55
	Annex 1_Questionnaire 2	67
Chapter 2.2	Risk attitudes and personality traits	71
	Annex 2_Questionnaire 1	93
Chapter 2.3	Assessing importance of benefits and risks in a clinical dossier	103
	Annex 3_Questionnaire 1	117
	Annex 1_Graphs	127
Chapter 3	Quantitative Assessment of Benefits and Risks	149
Chapter 3.1	Is quantitative benefit–risk modelling of drugs desirable or possible?	151
Chapter 4	The VALuE Study	167
Chapter 4.1	Value judgements among Multiple Sclerosis patients	169
Chapter 4.2	Values judgements among European regulators and patients	199
	Annex 4_Questionnaire 1	219
Chapter 5	Discussion and Conclusions	255
Chapter 6	Summary and Samenvatting	271
Chapter 6.1	Summary	273
Chapter 6.2	Samenvatting	283
Chapter 7	Addendum	293
Chapter 7.1	Acknowledgements	295
Chapter 7.2	List of Co-authors	301
Chapter 7.3	List of Publications	305
Chapter 7.4	About The Author	309
Chapter 7.5	List of SHARE Dissertations	313

